Diagnosis and analysis of a sebaceous gland tumour of the external acoustic meatus in a Cocker Spaniel dog

Sebaceous gland tumour (SGT) is a rare tumour with a low incidence rate, which mainly occurs in the eyelid and periocular sebaceous gland. In 2019, our laboratory received a case involving a sebaceous gland tumour of the external auditory meatus for pathological diagnosis. It is a rare malignant tumour in the whole body. Data regarding a sebaceous gland tumour in the dogís external auditory meatus are few. This case is instructive for veterinary diagnosis and treatment. The dog recovered well after surgery at the outpatient department, and no recurrence was observed in the follow-up visit one year later. This study will help the identification of SGT in Spaniel dogs.

Download Full-text

Well-differentiated Thyroid Carcinoma of Childhood and Adolescence- A Long Term Experience at a Single Institute

Bangladesh Journal of Nuclear Medicine ◽

10.3329/bjnm.v20i2.37345 ◽

2018 ◽

Vol 20 (2) ◽

pp. 99

Author(s):

Faria Nasreen ◽

Nurun Nahar ◽

Sadia Sultana

Keyword(s):

Thyroid Carcinoma ◽

Papillary Carcinoma ◽

Differentiated Thyroid Carcinoma ◽

Whole Body ◽

Childhood And Adolescence ◽

Children And Adolescent ◽

Number Of Patients ◽

Well Differentiated ◽

One Year

Background: Thyroid carcinoma is rare in childhood and adolescence. The presentation is more advanced in case of children as compared to adults. However, the prognosis for survival in children is reportedly excellent. The aim of the study was to see the outcome of patients with well differentiated thyroid carcinoma during childhood and adolescence treated at a single institute.Patients and methods: A retrospective study of 61 children and adolescent patients (age ≤18years) with well differentiated thyroid carcinoma (DTC) enrolled in the National Institute of Nuclear Medicine and Allied Sciences, Dhaka during the period of January1986 up to December 2007 was carried out. To allow for a theoretical follow up of at least 5 years the last inclusion year was 2007 and follow up was carried on up to June 2013. All patients were treated by thyroidectomy followed by radioiodine ablation therapy. Whole body scans, Tg, anti Tg Ab and neck ultrasound findings were recorded six months to one year after initial therapy to classify patients into remission, persistent or recurrent disease. Status on last follow up was noted to estimate the survival rate.Results: A total of 40 patients had papillary carcinoma, 18 had follicular variant of papillary carcinoma (FVPCT) and three had follicular carcinoma. Age range at diagnosis was nine to 18 years with a mean of 15± 2 years. The number of patients ≤10 years were five and > 10 years were 56. There were 12 males and 49 females giving a M: F ratio of about 1:4. Among the 61 patients 30 patients had lymph node metastases and two had both nodal and lung metastases at initial presentation. After one year follow up from the initial radioiodine therapy, 30 patients were in remission and 31 patients had persistent disease. Eventually recurrence occurred in five patients. Three patients died during the whole observation period and all of them were cancer related giving a cancer specific mortality ratio of 0.049%, 95% CI 0 to 0.105%. Cancer specific survival by Kaplan-Meier curve was 98.2%, 98.2% and 66% at 5, 10 and 15 years respectively.Conclusion: DTC in children and adolescent has a good prognosis in the presence of neck and distant metastases. Awareness of the patient and regular follow up with life long surveillance is essential to obtain a favorable outcome.Bangladesh J. Nuclear Med. 20(2): 99-104, July 2017

Download Full-text

Low frequency of disease flare in patients with rheumatic musculoskeletal diseases who received SARS-CoV-2 mRNA vaccine

Arthritis Research & Therapy ◽

10.1186/s13075-021-02674-w ◽

2022 ◽

Vol 24 (1) ◽

Author(s):

Francesca Romana Spinelli ◽

Ennio Giulio Favalli ◽

Cristina Garufi ◽

Martina Cornalba ◽

Serena Colafrancesco ◽

...

Keyword(s):

Incidence Rate ◽

Musculoskeletal Diseases ◽

Connective Tissue Diseases ◽

Low Frequency ◽

Vaccine Safety ◽

Control Group ◽

Multivariable Logistic Regression Analysis ◽

Disease Reactivation ◽

Low Incidence

Abstract Background Little is known about the safety of SARS-CoV-2 vaccination in patients with rheumatic musculoskeletal disease (RMD). We evaluated the occurrence of adverse events following immunization (AEFI) in RMD patients and heathy subjects who received anti-SARS-CoV-2 mRNA vaccine. Methods We performed a telephone interview collecting any adverse event (AE) following immunization (AEFI) that occurred in RMD patients and healthy controls after the two doses of mRNA vaccine including common local reactogenicity and systemic events (for example, fever, fatigue/malaise, joint and muscle pain). We also investigated the onset of new signs or symptoms of the RMD after the vaccination. Results We evaluated 126 patients with RMDs [105 females and 19 males, median age 51(IQR 17)] and 85 controls [62 females and 23 males, (median age 49 (20)]. Seventy patients (55.6%) were taking immunosuppressants, conventional synthetic (n=31, 43.3%) and/or biological [TNF inhibitors (n=49, 68.6%)], and 30 (23.8%) were taking hydroxychloroquine; treatment remained unchanged in 77% of patients. Eleven out of 126 patients and none of the 85 controls previously contracted COVID-19. The median follow-up from the completion of vaccination was 15 (3) weeks both in patients and controls. We reviewed 5 suspected cases confirming mild articular flares in 3 women (2.8) with inflammatory arthritis (2 psoriatic arthritis and 1 rheumatoid arthritis) while no disease reactivation was recorded in patients with connective tissue diseases; the incidence rate of RMD reactivation was 0.007 person/month. Multivariable logistic regression analysis showed similar frequencies of local and systemic AEFI in patients and controls with no effect of therapies or previous COVID-19. Local reaction—pain in the injection site—was the most frequently reported AEFI both in RMD and controls (71% and 75% of all the AEFI, respectively) after the first dose. Overall, up to 66% of patients experienced at least one AEFI at the second dose and up to 62% in the control group. Most of AEFI occurred within 2 days of vaccine administration. Two RMD patients developed pauci-symptomatic COVID-19 after the first dose of vaccine. Conclusion The low incidence rate of disease reactivation and the similar AEFI occurrence compared to controls should reassure on mRNA vaccine safety in RMD patients.

Download Full-text

Semi-Automatic MRI Muscle Volumetry to Diagnose and Monitor Hereditary and Acquired Polyneuropathies

Brain Sciences ◽

10.3390/brainsci11020202 ◽

2021 ◽

Vol 11 (2) ◽

pp. 202

Author(s):

Friederike S. Bähr ◽

Burkhard Gess ◽

Madlaine Müller ◽

Sandro Romanzetti ◽

Michael Gadermayr ◽

...

Keyword(s):

Chronic Inflammatory Demyelinating Polyneuropathy ◽

Spin Echo ◽

Whole Body ◽

Whole Body Mri ◽

Charcot Marie Tooth Disease ◽

Leg Muscles ◽

One Year ◽

Magnet Resonance ◽

Tooth Disease

With emerging treatment approaches, it is crucial to correctly diagnose and monitor hereditary and acquired polyneuropathies. This study aimed to assess the validity and accuracy of magnet resonance imaging (MRI)-based muscle volumetry.Using semi-automatic segmentations of upper- and lower leg muscles based on whole-body MRI and axial T1-weighted turbo spin-echo sequences, we compared and correlated muscle volumes, and clinical and neurophysiological parameters in demyelinating Charcot-Marie-Tooth disease (CMT) (n = 13), chronic inflammatory demyelinating polyneuropathy (CIDP) (n = 27), and other neuropathy (n = 17) patients.The muscle volumes of lower legs correlated with foot dorsiflexion strength (p < 0.0001), CMT Neuropathy Score 2 (p < 0.0001), early gait disorders (p = 0.0486), and in CIDP patients with tibial nerve conduction velocities (p = 0.0092). Lower (p = 0.0218) and upper (p = 0.0342) leg muscles were significantly larger in CIDP compared to CMT patients. At one-year follow-up (n = 15), leg muscle volumes showed no significant decrease.MRI muscle volumetry is a promising method to differentiate and characterize neuropathies in clinical practice.

Download Full-text

Cognitive function predicts work disability among multiple sclerosis patients

Multiple Sclerosis Journal - Experimental Translational and Clinical ◽

10.1177/2055217318822134 ◽

2019 ◽

Vol 5 (1) ◽

pp. 205521731882213 ◽

Cited By ~ 2

Author(s):

Andrius Kavaliunas ◽

Petter Tinghög ◽

Emilie Friberg ◽

Tomas Olsson ◽

Kristina Alexanderson ◽

...

Keyword(s):

Multiple Sclerosis ◽

Cognitive Function ◽

Confidence Interval ◽

Incidence Rate ◽

Work Disability ◽

Rate Ratio ◽

Incidence Rate Ratio ◽

One Year ◽

Multiple Sclerosis Patients

Background In multiple sclerosis various aspects of cognitive function can be detrimentally affected. More than that, patients´ employment and social functioning is likely to be impacted. Objective To determine whether work disability among multiple sclerosis patients could be predicted by the symbol digit modalities test. Methods A register-based cohort study was conducted. Individual data on work disability, operationalised as annual net days of sickness absence and/or disability pension were retrieved at baseline, when the symbol digit modalities test was performed, after one-year and 3-year follow-up for 903 multiple sclerosis patients. The incidence rate ratios for work disability were calculated with general estimating equations using a negative binomial distribution and were adjusted for gender, age, educational level, family composition, type of living area and physical disability. Results After one year of follow-up, the patients in the lowest symbol digit modalities test quartile were estimated to have a 73% higher rate of work disability when compared to the patients in the highest symbol digit modalities test quartile (incidence rate ratio 1.73, 95% confidence interval 1.42‒2.10). This estimate after 3-year follow-up was similar (incidence rate ratio 1.68, 95% confidence interval 1.40‒2.02). Conclusion Cognitive function is to a high extent associated with multiple sclerosis patients’ future work disability, even after adjusting for other factors.

Download Full-text

Primary Thyroid Lymphoma

Bengal Journal of Otolaryngology and Head Neck Surgery ◽

10.47210/bjohns.2018.v26i2.182 ◽

2018 ◽

Vol 26 (2) ◽

pp. 122-126

Author(s):

Manish Gupta ◽

Ginni Datta ◽

Naiya Rao ◽

Eshita Dadwal

Keyword(s):

Needle Aspiration ◽

Whole Body ◽

Thyroid Lymphoma ◽

Aspiration Cytology ◽

Diagnostic Dilemma ◽

Management Protocol ◽

History Of ◽

Needle Aspiration Cytology ◽

One Year

Introduction Lymphoma primarily arising from thyroid gland is very rare. Most patients give a history of previous Hashimoto’s thyroiditis and hypothyroidism. Case Report We hereby report one such rare case, who presented with neck swelling and hoarseness. The fine needle aspiration cytology being inconclusive, the patient was taken up for near total thyroidectomy. The histopathology revealed it to be lymphoma, which was further confirmed on immunohistochemistry. The further whole body checkup showed it to be Stage IIE tumor. The patient received chemotherapy for residual mass in neck and is under follow-up for last one year with no recurrence. Discussion The case is being presented here due to its rarity, diagnostic dilemma and to discuss the management protocol for same.

Download Full-text

First-Line Radio-Immunotherapy of Newly Diagnosed, Advanced Follicular Non-Hodgkin Lymphoma with 131I-Rituximab: The INITIAL Study,

Blood ◽

10.1182/blood.v118.21.3719.3719 ◽

2011 ◽

Vol 118 (21) ◽

pp. 3719-3719 ◽

Cited By ~ 1

Author(s):

Andrew D McQuillan ◽

William BG Macdonald ◽

Michael F Leahy ◽

J Harvey Turner

Keyword(s):

Hodgkin Lymphoma ◽

Combination Chemotherapy ◽

Post Treatment ◽

Whole Body ◽

Chimeric Antibody ◽

Newly Diagnosed ◽

First Line ◽

Non Hodgkin Lymphoma ◽

One Year

Abstract Abstract 3719 Introduction: Radio-immunotherapy (RIT) with 131I-rituximab has demonstrated efficacy in relapsed and refractory non-Hodgkin lymphoma (NHL). 131I-tositumomab has been shown to be an effective first-line agent in follicular NHL with durable response. We aimed to evaluate the efficacy and safety of first-line 131I-rituximab RIT and the duration of response in previously untreated patients with follicular NHL, given that this radiolabeled chimeric antibody treatment can be repeated upon relapse. Methods: Fifty consecutive patients with newly diagnosed, symptomatic, advanced follicular NHL received a prescribed therapy activity of 131I-rituximab predicated upon a fixed, whole-body radiation dose of 0.75 Gy. All patients were treated as outpatients. All patients received a standard four-week course of rituximab at a dose of 375 mg/m2 in conjunction with the radionuclide therapy, and subsequent rituximab maintenance at 3-monthly intervals for one year. Response was determined by 18F-FDG PET/CT scans at baseline, and at 3 and 12 months post-treatment. Results: Overall response rate (ORR) at 3 months was 98%, with complete response (CR) seen in 38 patients (76%) and partial response (PR) in 11 patients (22%). Four patients (36%) assessed as having PR at 3 months converted to CR in the year following treatment, so that 84% of patients were in CR at one year. During median follow-up of 33 months (range 12–61 months) only one patient (2.6%) among those who had achieved CR has relapsed, while progressive disease has been seen in seven patients (64%) of those with PR at first post-treatment assessment. Only three of the seven patients with PD have so far required further treatment; one with local radiotherapy and two who have received combination chemotherapy. Median progression-free survival (PFS) has not yet been reached. Toxicity was limited to hematological Grade 4 neutropenia in 5 patients (10%) and thrombocytopenia in 5 patients (10%). One patient received a single platelet transfusion. There were no episodes of bleeding or infection. Three patients have died; one from transformed, aggressive NHL (the only non-responder) and the other two from non-hematological malignancies not apparent at study entry. Conclusion: First-line 131I-rituximab RIT of advanced follicular NHL is effective and safe. Early response rates are similar to those observed with combination chemotherapy and rituximab regimens. Durable CR is present in 82% of patients over a median follow-up of 33 months and median PFS has not yet been reached. Of those with documented PR at 3 months, approximately one-third subsequently converted to CR, while the remaining two-thirds developed PD. Disclosures: Off Label Use: radiolabelled rituximab.

Download Full-text

P1399SPARING EFFECT OF PERITONEAL DIALYSIS VS HEMODIALYSIS ON CHANGE OF BONE MINERAL DENSITY EVALUATED BY WHOLE-BODY DXA AFTER INITIATION OF DIALYSIS THERAPY AND ITS IMPACT ON CLINICAL OUTCOME

Nephrology Dialysis Transplantation ◽

10.1093/ndt/gfaa142.p1399 ◽

2020 ◽

Vol 35 (Supplement_3) ◽

Author(s):

Ken Iseri ◽

Longkai Li ◽

Abdul Rashid Tony Qureshi ◽

Xin Li ◽

Jonaz Ripsweden ◽

...

Keyword(s):

Linear Regression Analysis ◽

Whole Body ◽

First Year ◽

Multivariate Linear Regression Analysis ◽

Mineral Density ◽

Initiation Of Dialysis ◽

One Year ◽

Esrd Patients ◽

Cvd Mortality

Abstract Background and Aims Bone loss is associated with progression of cardiac calcification and increased mortality in end stage renal disease (ESRD) patients but the relations and underlying causes are unclear. We investigated factors associated with changes of bone mineral density (BMD) during the first year after initiation of dialysis and the association between BMD changes and subsequent mortality in ESRD patients. Method In a prospective study of 242 ESRD patients (median age 55 years, 61% men) starting dialysis, total BMD and BMD at specific bone sites (including seven subregions: head, arms, legs, trunk, hip, pelvis and spine) was assessed by whole body dual-energy X-ray absorptiometry (DXA) at baseline and one year after dialysis start. Framingham cardiovascular disease (CVD) risk score, body composition, nutritional status, handgrip strength, various biochemical biomarkers (white blood cell, hemoglobin, albumin, creatinine, calcium, phosphate, intact parathyroid hormone, triglyceride, cholesterol, HDL cholesterol and high-sensitivity C-reactive protein) were recorded. We used multivariate linear regression analysis for BMD change analysis. We followed patients from 12 months after initiating of dialysis until renal transplantation, death or end of 60 months follow-up. During follow-up, 59 patients (24%) died due to CVD (n=33) or other causes (n=26) and 95 patients (39%) underwent renal transplantation. Fine and Gray competing risk analysis was used to ascertain associations of BMD changes with all-cause and CVD-related mortality. Results From baseline to one year after initiation of dialysis, there was a significant decrease of BMDtotal and BMDleg, trunk, rib, pelvis and spine in hemodialysis (HD) patients, whereas no difference was seen in peritoneal dialysis (PD) patients. In multivariate linear regression analysis adjusting for several confounders, HD therapy - compared to PD therapy - was significantly associated with negative changes in BMDtotal (β=-0.15), BMDhead (β=-0.14), BMDleg (β=-0.18) and BMDtrunk (β=-0.16). The direction and extent of changes in BMD, i.e. increase of BMD, associated with statistically significant lower all-cause mortality risk for BMDtotal (sHR, 0.91), BMDhead (sHR 0.91) and BMDleg (sHR 0.92), while for CVD-mortality a significant association with BMD changes was found only for changes in BMDhead (sHR 0.92). Conclusion In patients starting on dialysis, PD therapy appeared to have a beneficial effect on BMD changes as compared to HD during the first year of dialysis therapy. This difference may have implications for clinical outcomes as the degree of bone loss was associated with subsequent mortality. Changes towards increased BMDtotal, BMDhead and BMDleg associated with lower all-cause mortality. For head region – which is known as a cortical bone rich site – positive BMD change associated also with lower CVD mortality suggesting that increase or maintenance of BMD of cortical bone rich sites may have stronger association with clinical outcome in ESRD than BMD of trabecular bone.

Download Full-text

Multicenter Analysis of Clinical Follow-Ups in Patients with a Star GK Cardiac Valve Replacement for More than One Year

The Heart Surgery Forum ◽

10.1532/hsf.1441 ◽

2016 ◽

Vol 19 (3) ◽

pp. 104

Author(s):

Mingwen Li ◽

Yingbin Xiao ◽

Daozhong Chen ◽

Liming Liu ◽

Liming Ma ◽

...

Keyword(s):

Valve Replacement ◽

Clinical Data ◽

Blood Component ◽

Left Heart Failure ◽

Replacement Surgery ◽

Low Incidence ◽

One Year ◽

Valve Model ◽

Valve Replacement Surgery

Background: Star GK valves were widely used in China, and we studied the clinical follow-up results of patients with Star GK valve implants for more than one year. Methods: Clinical data were collected from those patients who had Star GK valve implants for over one year. Patients were divided into three groups: (1) AVR group: received aortic valve replacement surgery. Based on the valve model this group was further sub-divided into two groups: 21A group, and 23A group; (2) MVR group: received mitral valve replacement surgery. Based on the valve model this group was further sub-divided into three groups: 25M group, 27M group, and 29M group; (3) DVR group: received combined replacement surgeries including AVR + MVR. According to postoperative follow-up time these patients were divided into two groups: 1-year group and 3-year group. Follow-up data were collected by telephone, outpatient visits, or correspondence. Clinical data were aggregated by professional data scientists to conduct independent analyses. Results: 959 patients were included in the study following Star GK valve implant. Follow-up after 1 year found that thrombosis occurred in 4 cases, hemorrhage in 15 cases, left heart failure in 13 cases, paravalvular leakage in 5 cases, and death due to cardiac causes in 2 cases. Conclusion: The long-term efficacy of Star GK valve implants was satisfactory with low incidence of valve-related complications, and following Star GK valve implant, valve and blood were highly compatible and blood component damage was minor. Very low incidence rate of thrombosis was observed following Star GK valve implant, however, attention should be paid to adjust the anticoagulation intensity.

Download Full-text

Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol

The British Journal of Psychiatry ◽

10.1192/bjp.174.1.23 ◽

1999 ◽

Vol 174 (1) ◽

pp. 23-30 ◽

Cited By ~ 150

Author(s):

Charles M. Beasley ◽

Mary Anne Dellva ◽

Roy N. Tamura ◽

Hal Morgenstern ◽

William M. Glazer ◽

...

Keyword(s):

Relative Risk ◽

Tardive Dyskinesia ◽

Incidence Rate ◽

Involuntary Movement ◽

Term Treatment ◽

Double Blind ◽

Long Term Treatment ◽

Blind Comparison ◽

One Year

BackgroundTardive dyskinesia is important in the side-effect profile of antipsychotic medication.AimsThe development of tardive dyskinesia was evaluated in patients treated with double-blind, randomly assigned olanzapine or haloperidol for up to 2.6 years.MethodsTardive dyskinesia was assessed by the Abnormal Involuntary Movement Scale (AIMS) and Research Diagnostic Criteria for Tardive Dyskinesia (RD-TD); it was defined as meeting RD-TD criteria at two consecutive assessments. The risk of tardive dyskinesia, the relative risk, incidence rate, and incidence rate ratio were estimated.ResultsThe relative risk of tardive dyskinesia for the overall follow-up period for haloperidol (n=522) v. olanzapine (n=1192) was 2.66 (95% CI=1.50–4.70). Based on data following the initial six weeks of observation (during which patients underwent medication change and AIMS assessments as frequently as every three days), the one-year risk was 0.52% with olanzapine (n=513) and 7.45% with haloperidol (n=114). The relative risk throughout this follow-up period was 11.37 (95% Cl=2.21–58.60).ConclusionOur results indicated a significantly lower risk of tardive dyskinesia with olanzapine than with haloperidol.

Download Full-text

Myxoma of the external auditory meatus

The Journal of Laryngology & Otology ◽

10.1017/s0022215100116019 ◽

1991 ◽

Vol 105 (5) ◽

pp. 364-366 ◽

Cited By ~ 4

Author(s):

T. Palva ◽

E. Saksela ◽

H. Ramsay

Keyword(s):

Tympanic Membrane ◽

External Auditory Meatus ◽

Canal Wall ◽

One Year ◽

Wall Following ◽

Anterior Canal

AbstractA case of myxoma of the external auditory meatus is described. The patient presented with a recurring tumour which had not been correctly diagnosed although the growth had been removed ten times over a period of two years. The tumour was skin covered, contained gelatinous material and was attached to the tympanic membrane and anterior canal wall. Following recognition of the tumour as myxoma, removal was performed with sufficiently wide margins and there has been no recurrence during follow-up for one year.

Download Full-text